$ALNY
ALNYLAM PHARMACEUTICALS, INC.

2016 Q2 Form 10-Q Financial Statement

#000119312516577773 Filed on May 04, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2016 Q1 2015 Q1
Revenue $8.700M $7.300M $18.50M
YoY Change 0.0% -60.54% 122.89%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $18.00M $21.10M $12.70M
YoY Change 23.29% 66.14% 42.7%
% of Gross Profit
Research & Development $83.17M $96.27M $58.04M
YoY Change 24.12% 65.89% 32.63%
% of Gross Profit
Depreciation & Amortization $4.000M $4.601M $3.690M
YoY Change -20.0% 24.69% 41.92%
% of Gross Profit
Operating Expenses $101.2M $117.4M $70.76M
YoY Change 23.93% 65.88% -74.49%
Operating Profit -$92.45M -$110.0M -$52.22M
YoY Change 26.74% 110.69% -80.59%
Interest Expense $2.100M $1.800M $1.000M
YoY Change 31.25% 80.0% 233.33%
% of Operating Profit
Other Income/Expense, Net $2.321M $7.054M $1.014M
YoY Change 45.79% 595.66% 303.98%
Pretax Income -$90.13M -$103.0M -$51.21M
YoY Change 26.32% 101.09% -80.95%
Income Tax $0.00 $0.00 -$400.0K
% Of Pretax Income
Net Earnings -$90.13M -$103.0M -$50.78M
YoY Change 25.56% 102.8% -79.77%
Net Earnings / Revenue -1035.97% -1410.6% -274.47%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.054M -$1.208M -$618.8K
COMMON SHARES
Basic Shares Outstanding 85.56M shares 85.14M shares 83.76M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $843.1M $979.7M $967.0M
YoY Change -10.31% 1.32% 45.3%
Cash & Equivalents $271.1M $231.3M $306.6M
Short-Term Investments $572.0M $748.4M $660.4M
Other Short-Term Assets $22.20M $27.60M $13.20M
YoY Change 47.02% 109.09% 57.14%
Inventory
Prepaid Expenses
Receivables $9.500M $8.800M $10.10M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $888.1M $1.050B $1.090B
YoY Change -13.71% -3.68% 61.73%
LONG-TERM ASSETS
Property, Plant & Equipment $55.39M $36.81M $21.17M
YoY Change 120.09% 73.93% 34.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $287.2M $228.6M $483.8M
YoY Change -37.13% -52.75% 23.89%
Other Assets $1.471M $1.471M $33.70M
YoY Change -92.53% -95.64%
Total Long-Term Assets $494.1M $266.9M $538.6M
YoY Change -1.5% -50.45% 32.58%
TOTAL ASSETS
Total Short-Term Assets $888.1M $1.050B $1.090B
Total Long-Term Assets $494.1M $266.9M $538.6M
Total Assets $1.382B $1.317B $1.629B
YoY Change -9.71% -19.15% 50.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.82M $17.44M $15.49M
YoY Change -18.4% 12.63% 207.44%
Accrued Expenses $37.55M $30.81M $14.43M
YoY Change 111.46% 113.52% -13.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $70.58M $66.37M $80.69M
YoY Change 5.97% -17.75% -3.74%
LONG-TERM LIABILITIES
Long-Term Debt $150.0M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.777M $1.373M $51.60M
YoY Change -96.8% -97.34% 5060.0%
Total Long-Term Liabilities $1.777M $1.373M $51.60M
YoY Change -96.8% -97.34% 5060.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $70.58M $66.37M $80.69M
Total Long-Term Liabilities $1.777M $1.373M $51.60M
Total Liabilities $283.7M $127.9M $132.3M
YoY Change 132.21% -3.31% 5.55%
SHAREHOLDERS EQUITY
Retained Earnings -$1.440B -$1.350B -$1.007B
YoY Change 33.42% 33.98% 18.91%
Common Stock $2.567B $2.548B $2.452B
YoY Change 3.95% 3.92% 37.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.098B $1.189B $1.497B
YoY Change
Total Liabilities & Shareholders Equity $1.382B $1.317B $1.629B
YoY Change -9.71% -19.15% 50.77%

Cashflow Statement

Concept 2016 Q2 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$90.13M -$103.0M -$50.78M
YoY Change 25.56% 102.8% -79.77%
Depreciation, Depletion And Amortization $4.000M $4.601M $3.690M
YoY Change -20.0% 24.69% 41.92%
Cash From Operating Activities -$70.20M -$83.60M -$26.30M
YoY Change 26.71% 217.87% -36.93%
INVESTING ACTIVITIES
Capital Expenditures -$12.60M $2.759M $2.110M
YoY Change 869.23% 30.76% 443.81%
Acquisitions
YoY Change
Other Investing Activities -$31.80M $129.8M -$339.2M
YoY Change -69.91% -138.27% -4.29%
Cash From Investing Activities -$44.30M $117.9M -$341.3M
YoY Change -58.6% -134.54% -10.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $496.4M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 154.3M 16.10M 599.0M
YoY Change 2073.24% -97.31% -16.68%
NET CHANGE
Cash From Operating Activities -70.20M -83.60M -26.30M
Cash From Investing Activities -44.30M 117.9M -341.3M
Cash From Financing Activities 154.3M 16.10M 599.0M
Net Change In Cash 39.80M 50.40M 231.4M
YoY Change -125.63% -78.22% -22.19%
FREE CASH FLOW
Cash From Operating Activities -$70.20M -$83.60M -$26.30M
Capital Expenditures -$12.60M $2.759M $2.110M
Free Cash Flow -$57.60M -$86.36M -$28.41M
YoY Change 6.47% 203.97% -32.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
95.00
CY2016Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
85560535 shares
CY2016Q1 us-gaap Assets
Assets
1316949000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
306580000
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
85463258 shares
CY2016Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
85463258 shares
CY2016Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
66369000
CY2016Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
53952000
CY2016Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30805000
CY2016Q1 us-gaap Liabilities
Liabilities
127898000
CY2016Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
1178000
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
855000
CY2016Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2546884000
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
279000
CY2016Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1373000
CY2016Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
16944000
CY2016Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9011000
CY2016Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1349677000
CY2016Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
6204000
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
1189051000
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1316949000
CY2016Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
17442000
CY2016Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36814000
CY2016Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
228590000
CY2016Q1 us-gaap Assets Current
AssetsCurrent
1050074000
CY2016Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
228532000
CY2016Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
748722000
CY2016Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
748422000
CY2016Q1 us-gaap Available For Sale Securities Equity Securities Current
AvailableForSaleSecuritiesEquitySecuritiesCurrent
33934000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
231278000
CY2016Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
977012000
CY2016Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
8814000
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
521000
CY2016Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
228590000
CY2016Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
27626000
CY2016Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
977254000
CY2016Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1471000
CY2016Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
748422000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75179000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
85090968 shares
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-26255000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
85090968 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62099000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
52965000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28798000
CY2015Q4 us-gaap Liabilities
Liabilities
121796000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
1162000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
851000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2506197000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
32000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1301000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
15352000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4369000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1246703000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
5431000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
1264714000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1386510000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16787000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27812000
CY2015Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
251839000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
1105388000
CY2015Q4 us-gaap Available For Sale Securities Equity Securities Current
AvailableForSaleSecuritiesEquitySecuritiesCurrent
51419000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
180895000
CY2015Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1100056000
CY2015Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
8298000
CY2015Q4 us-gaap Assets
Assets
1386510000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2355000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
16559000
CY2015Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1102379000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1471000
CY2015Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
848217000
CY2015Q4 alny Litigation Damages Sought
LitigationDamagesSought
8000000
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5447368 shares
CY2015Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
496400000
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
21100000
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7805000 shares
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
82074000 shares
CY2015Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
507617000
CY2015Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
168687000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
70759000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47155000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2110000
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-52222000
CY2015Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-29830000
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-51208000
CY2015Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
18537000
CY2015Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
288000
CY2015Q1 us-gaap Investment Income Net
InvestmentIncomeNet
1014000
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1014000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3179000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-50777000
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3622000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
496400000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
598984000
CY2015Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3690000
CY2015Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-8432000
CY2015Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
13566000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12724000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6189000
CY2015Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
89018000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
231401000
CY2015Q1 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
247000
CY2015Q1 us-gaap Income Tax Expense Benefit Intraperiod Tax Allocation
IncomeTaxExpenseBenefitIntraperiodTaxAllocation
-431000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
750000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
8236000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-341328000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58035000
CY2016Q1 dei Document Type
DocumentType
10-Q
CY2016Q1 dei Trading Symbol
TradingSymbol
ALNY
CY2016Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001178670
CY2016Q1 dei Document Period End Date
DocumentPeriodEndDate
2016-03-31
CY2016Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10368000 shares
CY2016Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2759000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5241000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-110028000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-83623000
CY2016Q1 dei Amendment Flag
AmendmentFlag
false
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.21
CY2016Q1 dei Entity Registrant Name
EntityRegistrantName
ALNYLAM PHARMACEUTICALS, INC.
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Use of Estimates</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
85277000 shares
CY2016Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
164561000
CY2016Q1 us-gaap Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments
AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments
5156000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-116354000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2579000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21100000
CY2016Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
516000
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-102974000
CY2016Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
7345000
CY2016Q1 us-gaap Investment Income Net
InvestmentIncomeNet
1813000
CY2016Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
59000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7054000
CY2016Q1 us-gaap Payments For Capital Improvements
PaymentsForCapitalImprovements
9057000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2010000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-102974000
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8224000
CY2016Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
294317000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
117373000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
16066000
CY2016Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
5156000
CY2016Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4601000
CY2016Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-4305000
CY2016Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1824000
CY2016Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
14301000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
50383000
CY2016Q1 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
331000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
347000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
23480000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
117940000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96273000
CY2016Q1 alny Investment Maturity Period Minimum
InvestmentMaturityPeriodMinimum
P90D
CY2016Q1 alny Investments Classified As Cash And Cash Equivalent Original Maturities
InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities
P90D

Files In Submission

Name View Source Status
0001193125-16-577773-index-headers.html Edgar Link pending
0001193125-16-577773-index.html Edgar Link pending
0001193125-16-577773.txt Edgar Link pending
0001193125-16-577773-xbrl.zip Edgar Link pending
alny-20160331.xml Edgar Link completed
alny-20160331.xsd Edgar Link pending
alny-20160331_cal.xml Edgar Link unprocessable
alny-20160331_def.xml Edgar Link unprocessable
alny-20160331_lab.xml Edgar Link unprocessable
alny-20160331_pre.xml Edgar Link unprocessable
d166732d10q.htm Edgar Link pending
d166732dex101.htm Edgar Link pending
d166732dex102.htm Edgar Link pending
d166732dex103.htm Edgar Link pending
d166732dex311.htm Edgar Link pending
d166732dex312.htm Edgar Link pending
d166732dex321.htm Edgar Link pending
d166732dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g166732img001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending